Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 6,432 matching trials from the live ClinicalTrials.gov search.
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Protein Loading on Measurement of Renal Reserve

NCT07335614
Conditions
Glomerular Filtration Rate
Interventions
Lumitrace, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Conditions
Chronic Kidney Diseases, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Denver, Colorado • Newark, Delaware • Nampa, Idaho + 2 more
Completed No phase listed Observational

B-Receptor Signaling in Cardiomyopathy

NCT01135849
Conditions
Carcinomas, Amyloidosis, Anal Cancer, Anemia, Cholangiocarcinoma of the Extrahepatic Bile Duct, Transitional Cell Carcinoma of Bladder, Bone Marrow Transplant Failure, Bone Cancer, Cancer of Brain and Nervous System, Breast Cancer, Carcinoma of the Large Intestine, Endocrine Cancer, Esophageal Cancer, Eye Cancer, Gall Bladder Cancer, Gastric (Stomach) Cancer, Gastrooesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Gynecologic Cancers, Head and Neck Cancers, Hepatobiliary Neoplasm, Kidney (Renal Cell) Cancer, Leukemia, Lung Cancer, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mesothelioma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Neuroendocrine Tumors, Myeloproliferative Disorders, Pancreatic Cancer, Prostate Cancer, Skin Cancer, Soft Tissue Sarcoma, Testicular Cancer, Thymus Cancer, Thyroid Cancer
Interventions
Not listed
Lead sponsor
Daniel Bernstein
Other
Eligibility
Up to 40 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin alfa or Epoetin beta
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • McGehee, Arkansas + 33 more
Conditions
Chronic Kidney Disease Associated Moderate to Severe Pruritus
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
47
States / cities
Bakersfield, California • Glendale, California • La Palma, California + 40 more
Conditions
Renal Cell Carcinoma (Kidney Cancer)
Interventions
111In-XYIMSR-01
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Completed No phase listed Observational

ADPKD Cohort Study

NCT02084849
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Up to 60 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Leukemia, Lymphoma, Hodgkin's Disease, Hematologic Neoplasms, Multiple Myeloma, Carcinoma, Renal Cell
Interventions
Pentostatin, Alemtuzumab, Allogeneic hematopoietic stem cell transplantation
Drug · Biological · Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Tucson, Arizona
Terminated Phase 2 Interventional Results available

Imaging Studies of Kidney Cancer Using 18F-VM4-037

NCT01712685
Conditions
Carcinoma, Renal Cell, Kidney Neoplasms
Interventions
18F-VM4-037, PET/CT
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Results available

A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria

NCT03095885
Conditions
Secondary Hyperoxaluria, Nephrolithiasis, Hyperoxaluria, Kidney Stones
Interventions
Test Meal
Other
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Tucson, Arizona • Little Rock, Arkansas • Shreveport, Louisiana + 2 more
Conditions
Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non Small Cell Lung Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Thyroid Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Colon Cancer, Soft Tissue Sarcoma
Interventions
MGD009
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Conditions
HIV Infections, Kidney Failure, Chronic
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
End Stage Renal Disease
Interventions
Conventional hemodialysis, Frequent hemodialysis
Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
13 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Conditions
Pediatric Kidney Disease, Acute Kidney Injury
Interventions
HF20™
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Palo Alto, California • Cincinnati, Ohio • Seattle, Washington
Conditions
Renal Impairment, Healthy
Interventions
PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
4
States / cities
Lake Forest, California • Orlando, Florida • Tampa, Florida + 1 more
Active, not recruiting Not applicable Interventional Results available

Safety and Effectiveness of the Ultrasonic Propulsion of Kidney Stones

NCT02028559
Conditions
Kidney Stones, Nephrolithiasis, Urolithiasis
Interventions
Propulse 1 with C5-2 probe, Propulse 1 with SC-X probe
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
2
States / cities
Seattle, Washington
Conditions
Fall, Congestive Heart Failure, Chronic Kidney Failure, Adverse Drug Event
Interventions
Commitment nudge, Justification nudge
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 2 Interventional Results available

A Study of CCX140-B in Subjects With FSGS

NCT03536754
Conditions
FSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis
Interventions
Placebo, CCX140-B
Other · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Torrance, California • Shreveport, Louisiana + 6 more
Completed Phase 1 Interventional Accepts healthy volunteers

Study of CXA-10 in Healthy Volunteers

NCT02127190
Conditions
Acute Kidney Injury (Nontraumatic)
Interventions
CXA-10 emulsion, Placebo
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Kalamazoo, Michigan
Completed Phase 3 Interventional Results available

Pharmacokinetic Comparison Of All FK-506 Formulations

NCT02339246
Conditions
Renal Failure
Interventions
Prograf vs Envarsus XR vs Astagraf XL, Prograf vs Astagraf XL vs Envarsus XR
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Chronic Kidney Disease
Interventions
Sevelamer carbonate, Calcium acetate
Drug
Lead sponsor
Albany College of Pharmacy and Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Albany, New York
Conditions
Kidney Diseases
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies
Interventions
Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
Drug
Lead sponsor
LaTonya J. Hickson
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Recruiting Phase 1 Interventional Accepts healthy volunteers

Sympatholysis in Chronic Kidney Disease

NCT02411773
Conditions
Chronic Kidney Disease
Interventions
Sodium Bicarbonate, Placebo, Exercise Training, Control to Exercise (Stretching)
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Decatur, Georgia